We are an emerging leader with new solutions in the field of nuclear medicine technology

Our innovative products and technologies are designed to meet current and future demands for medical radioisotopes. They mark a new era for nuclear medicine technology.

Discover our Products

Supply

Medical radioisotopes are critical to meet patient healthcare needs and advance clinical research. We’ve charted the course for producing a stable, reliable and domestically sourced isotope supply.

Explore our Processes

Commitment

Our people drive our solutions. From providing domestic supply of isotopes for patients to national security and environmental sustainability, we are committed to advancing radioisotope technology to shape a better world.

Learn More

About NorthStar

We are a nuclear medicine technology company committed to providing the United States with stable, domestic and environmentally friendly radioisotope supply solutions to meet the needs of patients and advance clinical research. Our innovative technologies have the ability to fundamentally transform the ways that medical radioisotopes are produced and distributed around the world.

Learn More About NorthStar

Inside NorthStar

August 20, 2019

Purdue University College of Pharmacy and NorthStar Medical Radioisotopes Announce Collaborative Agreement Expanding Nuclear Pharmacy Training Curriculum

Beloit, Wis. and W. Lafayette, Ind., August 20, 2019 – NorthStar Medical Radioisotopes, LLC and Purdue University’s College of Pharmacy today announced a collaborative agreement which expands the College of Pharmacy’s nuclear pharmacy training program.

Press Releases

July 23, 2019

NorthStar Medical Radioisotopes Awarded $30 Million Cooperative Agreement by U.S. Department of Energy’s National Nuclear Security Administration to Expand Domestic Molybdenum-99 (Mo-99) Production

– Supports enhancements for commercially available RadioGenix® System and technology to increase NorthStar’s current production capacity of non-uranium based Mo-99 – BELOIT, Wis.

Press Releases

July 17, 2019

NorthStar Medical Radioisotopes Announces Construction Completion of Beloit, Wisconsin Processing Facility for Expanded Domestic Production of Medically Important Molybdenum-99 (Mo-99)

─ Facility part of staged, dual production pathway plan to expand Mo-99 production and efficiency in parallel with RadioGenix® System enhancements ─ RadioGenix System customers provided with reliable Mo-99 supply throughout eight months since commercial launch, helping mitigate concurrent industry disruptions BELOIT, Wis.

We are an emerging leader with new solutions in the field of nuclear medicine technology

About NorthStar

How Can We Help?